Following two (2) years of sluggish revenue performance, GlaxoSmithKline Consumer Plc (GLAXOSMITH) ended 2022FY with double digit topline expansion, anchored on the recovery of its pharmaceutical segment. Revenue from the pharmaceutical segment (c.66% of revenue surged 10.50% YoY to NGN16.75bn (vs NGN15.16bn in 2021FY), anchored on higher prices of prescription medicine as well as higher sales volume in the segment.
